P
Pear Therapeutics
Pear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need
At a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- Boston, United States
- Listing
- Public via SPAC 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- JPJAZZ Venture Partners
- BCBridge Builders Collaborative
- AVArboretum Ventures
- NONovartis
- 5V5AM Ventures
Series B and later12 investors entered at this stage
- UVUniversity of Virginia
Temasek- SGShanda Group
- QMQUAD Investment Management
- PVPilot House Ventures
- EDEDBI
- DCDartmouth College
- KIKarolinska Institute
SoftBank
SoftBank Vision Fund- TPTrustbridge Partners
- UCUniversity of Southern California
Source: Dealroom Talent Intelligence.
Alumni founders
Former Pear Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
Eric LeuthartUnited States
ATAffini-T TherapeuticsEst. 2020
Arjun GoyalUnited States
NBNew Frontier BioEst. 2020
Kirthiga ReddyUnited StatesGlobal footprint
across markets
Patents
8 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pear Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pear Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

